1. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R.
Helicobacter pylori virulence and genetic geography. Science 1999;284:1328–1333.
2. Lee JH, Choi KD, Jung HY, et al. Seroprevalence of
Helicobacter pylori in Korea: a multicenter, nationwide study conducted in 2015 and 2016. Helicobacter 2018;23:e12463.
3. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG.
Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699–709.
4. Crowe SE.
Helicobacter pylori infection. N Engl J Med 2019;380:1158–1165.
5. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent
Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019;157:44–53.
6. El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for
Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol 2018;16:992–1002.e6.
7. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of
Helicobacter pylori infection. Am J Gastroenterol 2017;112:212–239.
8. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of
Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6–30.
9. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during
Helicobacter pylori eradication therapy: a pilot study. Digestion 2001;63:1–7.
10. Kim YJ, Chung WC. Eradication therapy for
Helicobacter pylori with diagnostic test for clarithromycin resistance. Korean J Helicobacter Up Gastrointest Res 2019;19:225–230.
11. Kwok A, Lam T, Katelaris P, Leong RW.
Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7:271–281.
12. Kwon SB, Lee KL, Kim JS, et al. Antibiotics-associated diarrhea and other gastrointestinal abnormal responses regarding
Helicobacter pylori eradication. Korean J Gastroenterol 2010;56:229–235.
13. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during
Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155–168.
15. Myllyluoma E, Ahlroos T, Veijola L, Rautelin H, Tynkkynen S, Korpela R. Effects of anti-
Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents 2007;29:66–72.
17. Oh B, Kim BS, Kim JW, et al. The effect of probiotics on gut microbiota during the
Helicobacter pylori eradication: randomized controlled trial. Helicobacter 2016;21:165–174.
18. Yap TW, Gan HM, Lee YP, et al.
Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PLoS One 2016;11:e0151893.
19. Khusnutdinova D, Grigoryeva T, Abdulkhakov S, et al. Gut microbiome shotgun sequencing in assessment of microbial community changes associated with H. pylori eradication therapy. BioNanoScience 2016;6:585–587.
20. Yanagi H, Tsuda A, Matsushima M, et al. Changes in the gut microbiota composition and the plasma ghrelin level in patients with
Helicobacter pylori-infected patients with eradication therapy. BMJ Open Gastroenterology 2017;4:e000182.
21. Hsu PI, Pan CY, Kao JY, et al.
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of
Bacteroidetes and
Actinobacteria. Helicobacter 2018;23:e12498.
22. Chen L, Xu W, Lee A, et al. The impact of
Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine 2018;35:87–96.
23. Gotoda T, Takano C, Kusano C, et al. Gut microbiome can be restored without adverse events after
Helicobacter pylori eradication therapy in teenagers. Helicobacter 2018;23:e12541.
24. He C, Peng C, Wang H, et al. The eradication of
Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter 2019;24:e12590.
26. Hsu PI, Pan CY, Kao JY, et al. Short-term and long-term impacts of
Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol 2019;34:1968–1976.
27. Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after
Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019;19:1109–1120.
28. Martín-Núñez GM, Cornejo-Pareja I, Coin-Aragüez L, et al.
H. pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota. PLoS One 2019;14:e0213548.
29. Olekhnovich EI, Manolov AI, Samoilov AE, et al. Shifts in the human gut microbiota structure caused by quadruple
Helicobacter pylori eradication therapy. Front Microbiol 2019;10:1902.
32. Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther 2020;51:505–526.
34. Park HS, Han DS. Management of antibiotics-associated diarrhea. Korean J Gastroenterol 2009;54:5–12.
37. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf 1993;9:346–364.
41. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to
Clostridium difficile, Clostridium perfringens, and
Staphylococcus aureus. J Clin Microbiol 2006;44:2785–2791.
42. Rupnik M, Wilcox MH, Gerding DN.
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526–536.
43. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 2008;57:850–860.
44. Awad RW, Ward KL, Hawker PC. Fulminant pseudomembranous colitis (PMC) following triple therapy for
Helicobacter pylori. J R Coll Surg Edinb 1994;39:319.
45. Teare JP, Booth JC, Brown JL, Martin J, Thomas HC. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol 1995;7:275–277.
46. Archimandritis A, Souyioultzis S, Katsorida M, Tzivras M.
Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate
Helicobacter pylori. J Intern Med 1998;243:251–253.
47. Nawaz A, Mohammed I, Ahsan K, Karakurum A, Hadjiyane C, Pellecchia C. Clostridium difficile colitis associated with treatment of
Helicobacter pylori infection. Am J Gastroenterol 1998;93:1175–1176.
48. Harsch IA, Hahn EG, Konturek PC. Pseudomembranous colitis after eradication of
Helicobacter pylori infection with a triple therapy. Med Sci Monit 2001;7:751–754.
49. Lau CF, Hui PK, Fung TT, et al. Pseudomembranous colitis without diarrhoea following
Helicobacter pylori eradication therapy. Hosp Med 2001;62:431–433.
50. Rai R, Rai S. Pseudomembranous colitis requiring surgical intervention following triple therapy for
Helicobacter pylori eradication. ANZ J Surg 2002;72:917–919.
51. Yoo JW, Hwang JH, Kim JW, et al. A case of Clostridium difficile-associated colitis after Helicobacter pylori eradication. Korean J Med 2005;69:763–766.
52. Kubo N, Kochi S, Ariyama I, Murata M, Furusyo N, Hayashi J. Pseudomembranous colitis after
Helicobacter pylori eradication therapy. Kansenshogaku Zasshi 2006;80:51–55.
53. Trifan A, Girleanu I, Cojocariu C, et al. Pseudomembranous colitis associated with a triple therapy for
Helicobacter pylori eradication. World J Gastroenterol 2013;19:7476–7479.
54. Sato S, Chinda D, Yamai K, et al. A case of severe pseudomembranous colitis diagnosed by colonoscopy after
Helicobacter pylori eradication. Clin J Gastroenterol 2014;7:247–250.
55. Nei T, Hagiwara J, Takiguchi T, et al. Fatal fulminant
Clostridioides difficile colitis caused by
Helicobacter pylori eradication therapy; a case report. J Infect Chemother 2020;26:305–308.
56. Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of
Helicobacter pylori is not associated with future
Clostridium difficile infection. Am J Gastroenterol 2020;115:716–722.
57. Beaugerie L, Metz M, Barbut F, et al.
Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis. Clin Gastroenterol Hepatol 2003;1:370–376.
58. Toffler RB, Pingoud EG, Burrell MI. Acute colitis related to penicillin and penicillin derivatives. Lancet 1978;2(8092 Pt 1): 707–709.
59. Högenauer C, Langner C, Beubler E, et al.
Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418–2426.
61. Yonei Y, Yoshizaki Y, Tsukada N, et al. Microvascular disturbances in the colonic mucosa in antibiotic-associated haemorrhagic colitis: involvement of platelet aggregation. J Gastroenterol Hepatol 1996;11:681–685.
62. Kim CH, Jo YJ, Cho JS, et al. A case of amoxicillin-induced segmental hemorrhagic colitis. Korean J Gastrointest Endosc 2003;27:234–238.
63. Lee JH, Myo KY, Park JB, Kim K, Suh JI. Case of antibioticassociated hemorrhagic colitis related with Helicobacter pylori eradication. Dongguk J Med 2011;18:232–236.
64. Hamada Y, Tanaka K, Yamada R, Takei Y. Hemorrhagic colitis induced by second-line
Helicobacter pylori eradication. Intern Med 2020;59:301–302.
65. Miller AM, Bassett ML, Dahlstrom JE, Doe WF. Antibiotic-associated haemorrhagic colitis. J Gastroenterol Hepatol 1998;13:1115–1118.
67. Ikegami R, Kamiya K, Iwashige H. Three cases of antibioticassociated hemorrhagic colitis after second-line therapy for
Helicobacter pylori. J Jpn Soc Coloproctol 2015;68:419–424.
69. Kajihara Y. Antibiotic-associated hemorrhagic colitis caused by second-line therapy for
Helicobacter pylori eradication. Chonnam Med J 2020;56:144–145.
70. Kwun KA, Ham JH, Kim EJ, et al. Antibiotics associated hemorrhagic colitis: a report of two cases. Korean J Gastrointest Endosc 2001;22:45–49.
71. Youn Y, Lee SW, Cho HH, Park S, Chung HS, Seo JW. Antibiotics-associated hemorrhagic colitis caused by
Klebsiella oxytoca: two case reports. Pediatr Gastroenterol Hepatol Nutr 2018;21:141–146.
72. Moulis H, Vender RJ. Antibiotic-associated hemorrhagic colitis. J Clin Gastroenterol 1994;18:227–231.
73. Hafeez M, Qureshi ZA, Khattak AL, et al.
Helicobacter pylori eradication therapy: still a challenge. Cureus 2021;13:e14872.
75. Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 2020;159:697–705.
76. Lü M, Yu S, Deng J, et al. Efficacy of probiotic supplementation therapy for
Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One 2016;11:e0163743.
78. Nyssen OP, Perez-Aisa A, Tepes B, et al. Adverse event profile during the treatment of
Helicobacter pylori: a real-world experience of 22,000 patients from the European registry on
H. pylori management (Hp-EuReg). Am J Gastroenterol 2021;116:1220–1229.
79. Jung HK, Kang SJ, Lee YC, et al. Evidence-based guidelines for the treatment of
Helicobacter pylori infection in Korea: 2020 revised edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261–287.
80. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334–339.
81. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292–307.
82. Cleary RK. Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment. Dis Colon Rectum 1998;41:1435–1449.